34 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics http://www.zacks.com/stock/news/418993/dow-30-stock-roundup-home-depot-earnings-impress-merck-to-buy-peloton-therapeutics?cid=CS-ZC-FT-418993 May 24, 2019 - The index suffered a difficult week as investors braced for a protracted U.S.-China trade war.
Roche (RHHBY) Up 6.3% YTD on Strong Demand for New Drugs http://www.zacks.com/stock/news/422851/roche-rhhby-up-63-ytd-on-strong-demand-for-new-drugs?cid=CS-ZC-FT-422851 May 31, 2019 - Roche's (RHHBY) performance has been strong in the year so far, driven by solid growth of Ocrevus, Perjeta, Tecentriq and Hemlibra.
Why Cancer-Fighting Stocks & ETFs Are Soaring http://www.zacks.com/stock/news/424108/why-cancer-fighting-stocks-etfs-are-soaring?cid=CS-ZC-FT-424108 Jun 03, 2019 - The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
Roche Presents Positive Data on Xolair & Updates From ASCO http://www.zacks.com/stock/news/423876/roche-presents-positive-data-on-xolair-updates-from-asco?cid=CS-ZC-FT-423876 Jun 03, 2019 - Roche (RHHBY) reports positive data from late-stage studies on allergic asthma drug, Xolair, for a new indication, and additional results on Tecentriq and Avastin combo at ASCO.
Merck's Keytruda Improves 5-Year Survival in Lung Cancer http://www.zacks.com/stock/news/423872/mercks-keytruda-improves-5-year-survival-in-lung-cancer?cid=CS-ZC-FT-423872 Jun 03, 2019 - Merck (MRK) presents longest follow-up data for Keytruda in advance lung cancer at ASCO 2019. The five-year overall survival rates in the Keytruda arm are better than historical rates
Novartis (NVS) Announces Various Data Presentations at ASCO http://www.zacks.com/stock/news/424089/novartis-nvs-announces-various-data-presentations-at-asco?cid=CS-ZC-FT-424089 Jun 03, 2019 - Novartis (NVS) announces a number of data presentations at the ASCO 2019 annual meeting.
AstraZeneca's Imfinzi Shows Long-Term Benefits in Lung Cancer http://www.zacks.com/stock/news/423951/astrazenecas-imfinzi-shows-long-term-benefits-in-lung-cancer?cid=CS-ZC-FT-423951 Jun 03, 2019 - AstraZeneca (AZN) presents follow-up data on Imfinzi from late-stage PACIFIC study evaluating it in lung cancer patients.
Why Merck (MRK) is a Great Dividend Stock Right Now http://www.zacks.com/stock/news/424931/why-merck-mrk-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-424931 Jun 05, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Company News For Jun 4, 2019 http://www.zacks.com/stock/news/424463/company-news-for-jun-4-2019?cid=CS-ZC--424463 Jun 04, 2019 - Companies In The News Are: EE,CY,AMGN,MRK
Was ASCO Quieter for Big Drug/Biotech Stocks This Year? http://www.zacks.com/stock/news/425444/was-asco-quieter-for-big-drug-biotech-stocks-this-year?cid=CS-ZC-FT-425444 Jun 06, 2019 - The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

Pages: 1234

Page 1>